Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[An experimental study on SRCA (subrenal capsule assay)--using immunosuppressive maneuvers].

H Kikuchi1, M Asamura, M Gamoh

  • 1Dept. of Clinical Cancer Chemotherapy, Tohoku University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1988
PubMed
Summary

The study evaluated immunosuppressive maneuvers for in vivo chemosensitivity testing in mice. Cyclophosphamide (EX)-treated mice are suitable for a six-day assay, while nude mice are better for a 12-day assay.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2000
Same author

Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.

Anti-cancer drugs·1999
Same author

[Phase I study of raltitrexed (ZD-1694)].

Gan to kagaku ryoho. Cancer & chemotherapy·1998
Same author

[TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies].

Gan to kagaku ryoho. Cancer & chemotherapy·1997
Same author

[TUT-7 phase I clinical study. TUT-7 Study Group].

Gan to kagaku ryoho. Cancer & chemotherapy·1997
Same author

[Serum selenium contents in cancer patients].

Gan to kagaku ryoho. Cancer & chemotherapy·1997

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Context:

  • The six-day Soluble Tumor Cell Assay (SRCA) is a promising in vivo chemosensitivity test.
  • A significant challenge with the six-day SRCA is the host's immune reaction influencing results.
  • This study investigates the impact of three immunosuppressive methods on tumor growth kinetics and host response.

Purpose:

  • To evaluate the effects of cyclophosphamide (EX), cyclosporin A (CSA), and total body irradiation (TBI) on tumor growth, host reaction, and antitumor effects.
  • To determine the optimal assay duration and mouse model for SRCA based on immunosuppressive treatments.
  • To assess the influence of these immunosuppressive maneuvers on tumor cell proliferation and drug toxicity.

Summary:

  • Tumor growth kinetics varied among the immunosuppressive groups: EX and CSA showed growth until day 16, while TBI showed growth until day 10.

Related Experiment Videos

  • Histological and flow cytometric analyses confirmed tumor cell preservation on day 14 (CSA) and day 6 (EX, TBI).
  • The labeling index of tumor cells was unaffected by immunosuppressive maneuvers, but drug toxicity was heightened in the CSA group.

    • Impact:

    • Suggests a six-day SRCA is feasible with EX-treated normal mice for chemosensitivity testing.
    • Recommends a 12-day SRCA using nude mice for more reliable chemosensitivity assessments.
    • Highlights the differential impact of immunosuppressive strategies on in vivo tumor models and drug efficacy evaluation.